Shield Therapeutics PLC, a specialty pharmaceutical company based in Gateshead, United Kingdom, operates within the Health Care sector, specifically focusing on the Pharmaceuticals industry. The company is publicly traded on the London Stock Exchange, with its financial activities denominated in GBX (British Pound Sterling). As of June 23, 2026, Shield Therapeutics PLC’s close price stood at 6.2 GBX. Over the past year, the company’s stock has experienced significant fluctuations, reaching a 52-week high of 12.5 GBX on January 15, 2026, and a 52-week low of 2.7 GBX on July 9, 2025. The market capitalization of Shield Therapeutics PLC is currently valued at 86,330,496.73 GBX.
The company’s strategic focus is on the development and commercialization of secondary care-focused pharmaceuticals. Among its key late-stage products are an innovative oral medication designed for the treatment of iron deficiency anemia and an iron-based phosphate binder aimed at addressing hyperphosphatemia issues. These products highlight Shield Therapeutics’ commitment to addressing critical healthcare needs through advanced pharmaceutical solutions.
Despite its promising product pipeline, Shield Therapeutics PLC has reported a negative price-to-earnings (P/E) ratio of -5.11, indicating that the company is currently not generating profits. This financial metric reflects the challenges faced by the company in achieving profitability, which may be attributed to the high costs associated with drug development and commercialization.
For stakeholders and interested parties seeking further information about Shield Therapeutics PLC and its offerings, the company maintains an official website at www.shieldtherapeutics.com . This platform provides comprehensive details about the company’s mission, product developments, and strategic initiatives within the pharmaceutical landscape.
